191 related articles for article (PubMed ID: 4025111)
1. The effect of bretylium and clofilium on dispersion of refractoriness and vulnerability to ventricular fibrillation in the ischemic feline heart.
Kowey PR; Friehling TD; O'Connor KM; Wetstein L; Kelliher GJ
Am Heart J; 1985 Aug; 110(2):363-70. PubMed ID: 4025111
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of the effect of bretylium on the ventricular fibrillation threshold in dogs.
Euler DE; Scanlon PJ
Am J Cardiol; 1985 May; 55(11):1396-401. PubMed ID: 3993577
[TBL] [Abstract][Full Text] [Related]
3. Electrophysiologic effects of bretylium tosylate on the canine heart during coronary artery occlusion and reperfusion.
Gibson JK; Stewart JR; Li YP; Lucchesi BR
J Cardiovasc Pharmacol; 1983; 5(4):517-24. PubMed ID: 6193345
[TBL] [Abstract][Full Text] [Related]
4. Effects of bretylium tosylate on inhomogeneity of refractoriness and ventricular fibrillation threshold in canine hearts with quinidine-induced long QT interval.
Inoue H; Toda I; Nozaki A; Matsuo H; Sugimoto T
Cardiovasc Res; 1985 Oct; 19(10):655-60. PubMed ID: 4053141
[TBL] [Abstract][Full Text] [Related]
5. Deleterious effects of bretylium on hemodynamic recovery from ventricular fibrillation.
Euler DE; Zeman TW; Wallock ME; Scanlon PJ
Am Heart J; 1986 Jul; 112(1):25-31. PubMed ID: 3728284
[TBL] [Abstract][Full Text] [Related]
6. Ischemia-induced conduction delay and ventricular arrhythmias: comparative electropharmacology of bethanidine sulfate and bretylium tosylate.
Kabell G
J Cardiovasc Pharmacol; 1989 Mar; 13(3):471-82. PubMed ID: 2471895
[TBL] [Abstract][Full Text] [Related]
7. The effect of beta-adrenergic blockade on vulnerability to ventricular fibrillation and inducibility of ventricular arrhythmia in short- and long-term feline infarction models.
Luketich J; Friehling TD; O'Connor KM; Kowey PR
Am Heart J; 1989 Aug; 118(2):265-71. PubMed ID: 2750648
[TBL] [Abstract][Full Text] [Related]
8. The antiarrhythmic and antifibrillatory actions of bretylium and its o-iodobenzyl trimethylammonium analog, UM-360.
Kniffen FJ; Lomas TE; Counsell RE; Lucchesi BR
J Pharmacol Exp Ther; 1975 Jan; 192(1):120-8. PubMed ID: 1123718
[TBL] [Abstract][Full Text] [Related]
9. Effect of thromboxane synthetase inhibition on vulnerability to ventricular arrhythmia following coronary occlusion.
O'Connor KM; Friehling TD; Kelliher GJ; MacNab MW; Wetstein L; Kowey PR
Am Heart J; 1986 Apr; 111(4):683-8. PubMed ID: 3953390
[TBL] [Abstract][Full Text] [Related]
10. Electrophysiologic effects of bretylium on canine ventricular muscle during acute ischemia and reperfusion.
Fujimoto T; Hamamoto H; Peter T; McCullen A; McCullen A; Melvin N; Mandel WJ
Am Heart J; 1983 Jun; 105(6):966-72. PubMed ID: 6858845
[TBL] [Abstract][Full Text] [Related]
11. Prevention of ventricular fibrillation by bretylium in a conscious canine model of sudden coronary death.
Holland K; Patterson E; Lucchesi BR
Am Heart J; 1983 May; 105(5):711-7. PubMed ID: 6846113
[TBL] [Abstract][Full Text] [Related]
12. Antifibrillatory action of bretylium: role of the sympathetic nervous system.
Kopia GA; Lucchesi BR
Pharmacology; 1987; 34(1):37-47. PubMed ID: 3575413
[TBL] [Abstract][Full Text] [Related]
13. Antiarrhythmic and electrophysiologic actions of clofilium in experimental canine models.
Kopia GA; Eller BT; Patterson E; Shea MJ; Lucchesi BR
Eur J Pharmacol; 1985 Oct; 116(1-2):49-61. PubMed ID: 4054216
[TBL] [Abstract][Full Text] [Related]
14. Bretylium tosylate: profile of the only available class III antiarrhythmic agent.
Anderson JL
Clin Ther; 1985; 7(2):205-24. PubMed ID: 3886143
[TBL] [Abstract][Full Text] [Related]
15. Experimental and clinical pharmacology of bretylium tosylate in acute myocardial infarction: a 15-year journey.
Puddu PE; Jouve R; Saadjian A; Torresani J
J Pharmacol; 1986; 17(3):223-43. PubMed ID: 3795968
[TBL] [Abstract][Full Text] [Related]
16. Effect of bretylium on cardiovascular changes induced by coronary occlusion in the cat.
Corr PB; Gillis RA
Eur J Pharmacol; 1975; 33(2):401-4. PubMed ID: 1183484
[TBL] [Abstract][Full Text] [Related]
17. Role of the adrenergic nerve terminal in digitalis-induced cardiac toxicity: a study of the effects of pharmacological and surgical denervation.
Lathers CM; Gerard-Ciminera JL; Baskin SI; Krusz JC; Kelliher GJ; Goldberg PB; Roberts J
J Cardiovasc Pharmacol; 1982; 4(1):91-8. PubMed ID: 6176806
[TBL] [Abstract][Full Text] [Related]
18. A method for quantitating antifibrillatory effects of drugs after coronary reperfusion in dogs: improved outcome with bretylium.
Wenger TL; Lederman S; Starmer CF; Brown T; Strauss HC
Circulation; 1984 Jan; 69(1):142-8. PubMed ID: 6689638
[TBL] [Abstract][Full Text] [Related]
19. The effect of newer antiarrhythmic drugs on defibrillation threshold.
Tacker WA; Niebauer MJ; Babbs CF; Combs WJ; Hahn BM; Barker MA; Seipel JF; Bourland JD; Geddes LA
Crit Care Med; 1980 Mar; 8(3):177-80. PubMed ID: 7363635
[TBL] [Abstract][Full Text] [Related]
20. Suppression of ventricular fibrillation and positive inotropic action of bethanidine sulfate, a chemical analog of bretylium tosylate that is well absorbed orally.
Bacaner MB; Hoey MF; Macres MG
Am J Cardiol; 1982 Jan; 49(1):45-55. PubMed ID: 7053610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
